TVTX Unusual Options Activity — 2026-01-14

📅 January 14, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just sold $2.4 MILLION worth of TVTX calls - a single massive trade that stands out as extremely unusual activity. This isn't your typical position management - this is institutional money taking chips off the table just days after the stock cratered 20% on the FDA delay news. With the FSGS decision now pushed to April 13, 2026, big players appear to be de-risking ahead of what could be a make-or-break binary event.

---

🏢 Company Overview

Travere Therapeutics (TVTX) is a biopharmaceutical company focused on rare kidney diseases. Their flagship drug FILSPARI (sparsentan) is already approved for IgA nephropathy and generating strong revenue - $103M in Q4 2025 alone (+108% YoY). The company is now awaiting FDA approval to expand FILSPARI's use to FSGS (focal segmental glomerulosclerosis), a disease with no current approved treatments affecting approximately 40,000 U.S. patients.

📊 Key Stats:

• 💵 Market Cap: ~$2.1B (post-selloff)
• 📍 52-Week Range: $12.91 - $42.13
• 🏦 Current Price: ~$27.90
• 💰 Cash Position: $323M

---

💰 The Option Flow Breakdown

📊 What Just Happened

This trade is significantly larger than typical TVTX option activity. For context, this kind of size happens only a handful of times per year.

🤓 What This Actually Means

Translation for us regular folks: A big player just collected $2.4M in premium by selling 2,800 January 2027 $30 calls. Here's what they're betting on:

✅ If TVTX stays below $30 by Jan 2027: They keep the entire $2.4M premium - pure profit

❌ If TVTX rallies hard: They're on the hook for potentially unlimited losses above $30

The $30 strike is sitting about 7.5% above current prices (~$27.90). This seller is essentially saying: "I'll take $2.4M today because I don't think TVTX is going much higher than $30 even with a full year to play out."

Given the FDA just pushed back the FSGS decision by 3 months and requested additional data, this trade suggests institutional skepticism about a smooth path to approval.

---

📈 Technical Setup / Chart Check-Up

YTD Chart

TVTX had been on a strong run through late 2025, climbing toward the $40 level on optimism about the FSGS approval. That all changed on January 13, 2026 when the FDA announced a 3-month delay, sending shares crashing from $34.10 to close around $23.29 - a brutal 32% intraday plunge before recovering to close down ~20%.

The stock has bounced back to the ~$27-28 area, but remains well below pre-delay levels.

🎯 Gamma-Based Support & Resistance Analysis

What the options market is telling us:

Net GEX Bias: Bearish (Total Put GEX: $5.46M vs Call GEX: $5.25M)

The $30 strike - exactly where today's big call sale occurred - represents the strongest resistance level. Market makers have massive exposure there with $5.16M total gamma. This creates a magnetic ceiling that will be hard to break without significant buying pressure.

Meanwhile, support clusters around $27.50 (just 1.4% below current price) and $25 (10% lower). If the stock breaks below $27.50, the next real floor is at $25.

📊 Implied Move Analysis

Current IV: 90.23% - Options are pricing in major volatility ahead. The weekly straddle costs $1.55 (~5.5% of stock price), reflecting elevated uncertainty.

Note the massive IV skew in weekly options: Call IV at 121% vs Put IV at 59%. This tells us the market is pricing in upside risk disproportionately - likely hedging activity around the FDA event.

---

🎪 Catalysts

📆 Upcoming (Next 6 Months)

✅ Recent Events (Already Happened)

---

🎲 Price Targets & Probabilities

Based on gamma levels, implied moves, and catalyst timing:

🐻 Bear Case: $22.50-$25.00 (30% probability)

• FDA issues Complete Response Letter (CRL) in April
• Stock tests January lows and potentially breaks lower
• Stifel's $25 target becomes the floor
• Implied move supports $22.75 by Q1

⚖️ Base Case: $27.50-$30.00 (45% probability)

• Stock consolidates in current range through February earnings
• Uncertainty persists until April PDUFA
• Gamma ceiling at $30 caps upside
• Implied move range: $27.21-$29.85 (weekly)

🐂 Bull Case: $34-$40+ (25% probability)

• FSGS approval comes through in April
• First-mover advantage in 40,000-patient market
• Analyst targets of $35-$48 come back into play
• Quarterly implied move supports $34.31 upside

---

💡 Trading Ideas

🛡️ Conservative: "Wait and Watch"

Strategy: Cash-secured put sale at support

• 📍 Sell TVTX Feb 21 2026 $25 Put
• 💵 Collect ~$1.50-2.00 premium per contract
• 🎯 Max profit: Keep premium if TVTX stays above $25
• ⚠️ Worst case: Assigned at $25, effective cost basis ~$23

Why this works: The $25 strike sits at strong put gamma support and is 10% below current prices. You're essentially getting paid to buy the stock at a discount if it crashes further.

---

⚖️ Balanced: "Earnings Play"

Strategy: Bull call spread through Q4 earnings

• 📍 Buy TVTX Mar 20 2026 $27.5 Call
• 📍 Sell TVTX Mar 20 2026 $32.5 Call
• 💵 Net debit: ~$2.50-3.00 per spread
• 🎯 Max profit: $5.00 spread width - debit = ~$2.00-2.50 (67%-83% return)
• ⚠️ Max loss: Premium paid

Why this works: Captures potential upside from strong Q4 earnings (Feb 19) while capping risk. The March expiration gives time for the stock to recover before the April PDUFA decision adds binary risk.

---

🚀 Aggressive: "FSGS Approval Bet"

Strategy: Long-dated call position

• 📍 Buy TVTX Jan 15 2027 $30 Call
• 💵 Cost: ~$8.50-9.00 per contract (current ask around $8.57 based on today's trade)
• 🎯 Breakeven: $38.50-39.00 by expiration
• 🎯 Target: $50+ on FSGS approval + commercial momentum
• ⚠️ Max loss: 100% of premium

Why this works: Today's $2.4M seller is on the other side of this trade - they're betting TVTX stays below $30. If you believe the FDA approves FILSPARI for FSGS in April, this gives you time for the thesis to play out with a year of runway.

Note: This is the same contract where someone just sold $2.4M worth. You'd be taking the opposite side of an institutional trade.

---

⚠️ Risk Factors

🔴 FDA Rejection Risk (40-50% probability per analysts): The FDA's request for additional "clinical benefit characterization" beyond proteinuria reduction suggests they want harder evidence. A Complete Response Letter (CRL) would likely send shares back to the $15-20 range.

🔴 Insider Selling Pattern: 12 insider transactions totaling $11.3M in sales over the past 3 months - all under 10b5-1 plans, but still notable.

🔴 Competition Heating Up: Novartis is building an "IgAN troika" with three drugs, and their atrasentan is advancing in FSGS Phase 2 trials.

🔴 Binary Event Risk: The April 13 PDUFA is an all-or-nothing catalyst. Options will be expensive heading into it, and the stock could move 30%+ either direction.

🔴 Today's Flow is Bearish: The $2.4M call sale suggests at least one large player is skeptical about upside potential.

---

🎯 The Bottom Line

Real talk: TVTX is a tale of two stories. On one hand, FILSPARI is crushing it commercially - record sales, 108% YoY growth, 908 new patient starts in Q4 alone. On the other hand, the FDA just threw a wrench in the FSGS expansion plans, and today's massive call sale shows institutional money isn't convinced the path forward is clear.

Here's the deal:

📈 If you're bullish: Wait for the February 19 earnings to confirm the commercial momentum story. Strong numbers could provide a floor before the April PDUFA. The balanced strategy (call spread) lets you play the earnings catalyst without full binary risk exposure.

👀 If you're watching: The $27.50 level is your line in the sand. As long as TVTX holds above this gamma support, the stock can consolidate and build a base. Break below it, and $25 is the next stop.

📉 If you're bearish: Today's flow supports your thesis. Selling covered calls or buying put spreads ahead of April makes sense if you believe the FDA sends a CRL.

Mark your calendar for:

• 📅 February 19, 2026 - Q4 Earnings
• 📅 April 13, 2026 - FSGS PDUFA Decision (the big one)

Bottom line: Don't try to be a hero ahead of a binary FDA event. The smart money is hedging, and you should too. Trade small, define your risk, and be prepared for anything.

---

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Options trading involves substantial risk and is not suitable for all investors. You could lose more than your initial investment. Always do your own research and consider your risk tolerance before trading.